- September 11, 2020– Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations – – Time Course of MRI Lesion Suppression Shows…
- September 8, 2020NEW YORK, September 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed…
- August 20, 2020NEW YORK, August 20, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- August 10, 2020NEW YORK, August 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…
- August 5, 2020NEW YORK, August 4, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed…
- August 3, 2020NEW YORK, August 3, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed…
- August 2, 2020– Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis –…
- July 30, 2020NEW YORK, July 30, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…
- July 29, 2020NEW YORK, July 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…
- July 27, 2020– Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust – NEW YORK, July 27, 2020 – Immunic,…
